SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate critical clinical trial results and a potential acquisition, fueling a technical short squeeze driven by record short interest. The community is actively discussing the stock's parabolic move and the strategic implications of recent corporate filings ahead of imminent trial data readouts.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix Inc. is trending as investors digest a strong earnings report and raised full-year guidance, with community discussion focused on the potential for institutional accumulation and the ongoing commercial buildout for the company's broader anti-infective platform. While some shareholders are debating the long-term growth outlook and patient adoption metrics, many are actively monitoring the stock's ability to maintain upward momentum as they look for catalysts beyond the DefenCath franchise.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc is currently attracting significant community attention following its latest quarterly earnings report, which highlighted record profitability and the launch of a $75 million share buyback program. While bulls are energized by these financial improvements and new strategic partnerships, the broader conversation remains divided as skeptics point to stalled policy growth and a history of volatility, leaving investors closely watching whether these new initiatives can sustain long-term momentum.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is trending due to strong financial performance and continued momentum in its defense-focused infrared optics and assembly business, which is benefiting from a push toward domestic sourcing. The community is actively discussing the company's strategic position in the U.S. defense supply chain, the ongoing replacement of Germanium with proprietary BlackDiamond materials, and potential involvement in high-profile military programs like the NGSRI.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is experiencing intense volatility as investors debate whether the recent surge represents a fundamental AI-driven rerate or a speculative bubble prone to a technical correction. Community discussions are heavily focused on the stock's parabolic trajectory and the potential for a sharp pullback, with many debating the optimal entry points amid concerns over market-wide valuation levels.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund is experiencing heightened volatility as investors weigh the impact of persistent supply disruptions in the Strait of Hormuz against ongoing, yet inconclusive, diplomatic negotiations between the U.S. and Iran. The community remains deeply divided, with many traders closely monitoring inventory depletion rates and shipping traffic as key indicators of whether the sector is facing a structural energy supply crisis or a temporary geopolitical premium.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

TOYO is seeing increased investor scrutiny as market participants debate the potential impact of an anti-circumvention probe and the stock's recent capital raise. While some community members express concern over the company's wafer supply chain and potential retroactive tariffs, others remain bullish on TOYO's domestic manufacturing ramp-up in Texas and its fundamental valuation.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending due to its emerging role in AI data center power infrastructure, with investors reacting positively to its new solid-state transformer technology and recent insider buying by the CEO. Community sentiment remains polarized, with bullish discussions focusing on a potential short squeeze and long-term data center opportunities, while bears continue to highlight concerns regarding residential solar market headwinds and rapid price volatility.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

JNUG is trending as investors react to escalating geopolitical instability in the Middle East and concerns over aggressive U.S. fiscal policies, which are driving renewed interest in gold miners as a hedge against currency debasement. The community is actively debating the sustainability of rising debt levels and the potential for increased volatility as traders weigh the impact of central bank liquidity measures on the gold sector.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is facing intense community volatility and selling pressure following an earnings call that provided no immediate deal catalysts, prompting concerns over dilution and a potential lack of near-term commercial traction. While some investors remain focused on the long-term potential of the firm's material science technology for semiconductor scaling, others are actively debating the timing of institutional support and the credibility of analyst price targets amidst management's focus on extended evaluation timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion Status Update: Experts Discuss Icovamenib's Promise Ahead of ADA 2026

Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre...

Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of Biomea Fusion in a research note on Tuesday. They issued a 'market outperform' rating and a $9.00 target price on the stock...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings...

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company's COVALENT-112 proof-of-concept...

Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research report on Tuesday...

Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-biomea-fusion-inc-stock...

Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research note on Wednesday...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment...

Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts

Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator...

Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes

Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes.

BMF-6...

This account has been verified as an official BMEA representative.

Verified Account

Biomea Fusion IR

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Biomea Fusion Inc

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.22	--	--	N/A
Q1 '26	-$0.23	-$0.17	26.50%	BEAT
Q4 '25	-$0.23	$0.40	273.77%	BEAT
Q3 '25	-$0.26	-$0.27	-5.37%	MISSED
Q2 '25	-$0.53	-$0.51	3.92%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMEABiomea Fusion Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BMEA News